(IBO) Impact BioMedical Inc. Company Overview

A hybrid intellectual-property and commercialization company

Impact BioMedical Inc. is a small, publicly traded healthcare and wellness company listed on NYSE American under the ticker IBO. It does not resemble a mature pharmaceutical manufacturer with a portfolio of approved drugs and recurring product revenue. Its core model is to discover, validate, acquire, patent, and position technologies for commercialization through licensing, co-development, joint ventures, distribution relationships, and selective direct sales. The company describes this partner-led approach on its official company overview.

One operating segment, several technology platforms

For accounting purposes, Impact BioMedical operates as one biotechnology segment. Strategically, however, the portfolio spans several distinct end markets: specialty biopharmaceuticals, antiviral and antimicrobial technologies, metabolic and nutrition applications, functional fragrances, and air purification. The official pipeline highlights Linebacker, Laetose, Equivir, and 3F, while the 2025 Celios acquisition added a physical air-filtration product line.

Licensing economics versus product sales

The intended model has two economic engines. The first is licensing: a partner may pay upfront fees, option fees, development milestones, regulatory milestones, commercialization milestones, and royalties on eventual sales. This can be capital-light for Impact BioMedical because the partner may carry much of the clinical, manufacturing, regulatory, and commercial burden. The second engine is direct or distributor-based product sales, currently represented by Celios air-purification products. The company’s 2025 Form 10-K explains both the licensing framework and the new retail-sales revenue stream.

The Celios shift toward near-term revenue

In February 2025, Impact BioMedical acquired Celios assets from related party DSS PureAir in an all-equity transaction valued at $1.15 million, issuing 545,024 shares. The acquired package included receivables, inventory, and intellectual property. The company presented Celios as a route to immediate product revenue and patented filtration capability with stated exclusivity through 2043 in its official acquisition announcement.

Which platform could create the largest option value?

Why patents matter more than current sales

The patent estate is the company’s central strategic resource. The 2025 filing reports rights or ownership to 69 issued patents and more than 60 pending patents worldwide, covering composition, method, and design claims. Breadth can improve negotiating leverage, create multiple licensing shots, and make a portfolio more attractive to a strategic buyer. It does not, by itself, prove clinical efficacy, regulatory approval, product-market fit, or royalty income.

Revenue is real but still immaterial

The newest official reporting package is the Form 10-Q for the quarter ended March 31, 2026. It shows $7,000 of revenue, all from biotech retail sales, against $2.296 million of costs and expenses. The operating loss was $2.289 million, and net loss was $2.284 million. These numbers confirm that Celios has crossed the line from zero sales to reported sales, but not that the commercial model has reached economic scale.

Expenses, equity awards, and cash burn

From IP assembly to public listing

1. 2017–2018
   Operating subsidiaries and core research platforms were assembled; Impact BioMedical itself was incorporated in Nevada in October 2018. This established the IP-holding structure used today.
2. 2020
   A share exchange moved Impact BioMedical under DSS BioHealth. The transaction shaped related-party funding, ownership concentration, and the later public-company pathway.
3. 2022
   Linebacker-1 and Linebacker-2 licensing agreements with ProPhase Laboratories provided a partner-led route for worldwide development and commercialization.
4. 2023–2024
   A 1-for-55 reverse split prepared the capital structure, and the company completed a 1.5 million-share IPO at $3.00 per share in September 2024. The IPO prospectus documents the offering and NYSE American listing.
5. 2024
   The U.S. patent allowance for Laetose strengthened one of the company’s most consumer-facing platforms and supported a broader international patent strategy.
6. 2025
   Impact acquired Celios for $1.15 million in stock, signed a reverse-merger agreement with Dr Ashleys, and converted approximately $15 million of related-party principal and interest into 31,939,778 common shares.
7. 2026
   The merger agreement was amended, extending its end date to July 1, 2026 and updating the proposed combined-company share allocation. The latest publicly filed amendment reviewed set July 1, 2026 as the contractual end date, extendable by written consent. This analysis does not assume a closing and treats the transaction as unresolved until an official closing, extension, or termination disclosure.

The Dr Ashleys transaction changes the scenario set

The proposed transaction would place Impact BioMedical and Dr Ashleys under a new Cayman Islands public holding company. The strategic logic is straightforward: combine Impact’s patent portfolio with pharmaceutical manufacturing, financing, and commercialization capabilities. The official merger announcement framed the combination as a path to accelerate technologies toward market.

The February 2026 Form 8-K amendment specified 169,560,000 PubCo ordinary shares for the Dr Ashleys shareholder, representing 94.20% of issued PubCo shares at closing before certain additional issuances. For IBO holders, the merger is therefore not merely an operating partnership; it would redefine ownership, governance, dilution, reporting, and the relevant financial base for valuation.

What is the moat?

Impact BioMedical’s strongest potential advantage is portfolio breadth combined with a partner-oriented operating model. A company with multiple composition, method, and design patents can pursue several markets without building a full commercial organization for every platform. That can create option value and reduce the need for vertically integrated clinical development. The scientific themes also span both regulated biopharmaceutical pathways and potentially faster consumer-wellness pathways, allowing different time-to-market profiles.

Who is the competition?

The company does not identify a clean set of public-company peers, and that is analytically important. It competes simultaneously with major pharmaceutical companies, specialty pharma, biotechnology developers, academic laboratories, government-backed research, private research institutions, consumer-health products, and air-purification vendors. Many alternatives have more capital, regulatory experience, manufacturing capacity, clinical infrastructure, and distribution reach. Impact therefore competes less through scale and more through the quality, protectability, and partnerability of specific inventions.

Annual losses improved, but the quality of improvement matters

FY2025 revenue was $32,000, compared with zero in FY2024. Total costs and expenses fell to $4.314 million from $28.753 million, largely because FY2024 included a $25.093 million goodwill impairment. FY2025 operating loss was $4.282 million, while net loss was $11.870 million. The gap reflects a $9.388 million fair-value loss on the related-party note, partly offset by a $2.580 million tax benefit. The lower net loss versus FY2024 therefore does not represent a simple operating turnaround.

Liquidity and asset concentration

At March 31, 2026, Impact BioMedical had $377,000 of current assets and $1.687 million of current liabilities, a current ratio of roughly 0.22x. Cash was only $20,000. Amounts due to related party DSS increased to $1.103 million from $621,000 at December 31, 2025, while Q1 financing cash flow included $482,000 of related-party borrowings. The filing states that recurring losses and negative operating cash flows create substantial doubt about the company’s ability to continue as a going concern.

Ownership and voting influence

Impact BioMedical has one common share class outstanding, but economic ownership is highly concentrated. The company’s 2025 Form 10-K, using 107,821,231 common shares outstanding as of March 6, 2026, reported DSS BioHealth Security with 60,496,041 shares, or 56.1%, and DSS Inc. with 32,484,802 shares, or 30.1%. Officers and directors as a group held 3,095,779 shares, or 2.9%.

Board, incentives, and controls

The 2025 proxy statement proposed eight directors, while the later annual report identified five directors as independent under NYSE American standards. The company maintains audit, compensation, and nominating/governance committees. However, the Q1 2026 filing also stated that previously disclosed material weaknesses remained and that disclosure controls were not effective. In January 2026, the company issued 3.2 million shares to executives, directors, audit-committee members, and others, recording $1.44 million of stock-based compensation in Q1.

For minority holders, governance analysis should focus on related-party transactions, equity issuance, the terms of any merger extension or closing, and whether improved internal controls keep pace with a more complex corporate structure.

Growth catalysts

Impact BioMedical has several ways to create a step-change from its current scale. A licensing agreement with meaningful upfront economics would validate the IP model without requiring large direct-product volume. Better Celios distribution could build a recurring revenue base. Patent allowances can improve bargaining leverage. A strategic combination could add manufacturing, regulatory, and commercial infrastructure. Because the current revenue base is extremely small, even a modest contract can create a large percentage change—although percentage growth from a tiny base should not be confused with durable economics.

Risks are concentrated in financing, execution, and evidence

A conventional steady-state DCF is not the first tool

Impact BioMedical has too little recurring revenue and too much event dependence for a standard mature-company DCF built from smooth revenue growth, stable margins, and predictable reinvestment. The model should instead separate observable operations from contingent option value. A base case can model Celios sales, operating expenses, cash burn, related-party financing, and dilution. Separate probability-weighted cases can address licensing milestones, royalties, regulatory progress, patent monetization, and the Dr Ashleys transaction.